VVT Medical (TSXv:VVTM) advances vein care with minimally invasive, office-based treatments that reduce procedural complexity, recovery time, and adverse effects.
Our proprietary products deliver precise, controlled therapy for patients with varying venous pathologies.
VVT’s product portfolio includes ScleroSafeTM and V-BlockTM, two synergistic, catheter-based solutions designed to treat the widest range of vein diameters in the market.
Leveraging a proprietary mechanochemical technology that combines controlled sclerosant injection and simultaneous vessel collapse and blood aspiration, our products deliver effective vein closure with minimal side effects.
It marked the beginning of our next chapter as a publicly traded company and reinforced our commitment to advancing venous care through innovative, non-thermal, minimally invasive solutions.
Under the agreement, Medworks - a leading healthcare distributor in India - will be responsible for the marketing, sales, and distribution of the ScleroSafe™ platform across the Indian market, leveraging its established network and deep expertise in advanced healthcare technologies.
We were honored to welcome Prof. Ralf Kolvenbach, esteemed vascular surgeon and distinguished member of the VVT Medical Advisory Board, to our booth. We met with numerous interested distributors, physicians, and potential partners who were fascinated by our technology.
“That was painless!” was the patient’s first reaction. Huge thanks to Dr. Antonios Gasparis, System Chief of Vein Disease and the entire Northwell team for their trust and professionalism.
Led by Dr. Steve Elias with co-chairs Dr. Antonios Gasparis and Dr. Nicos Labropoulos, EVM stands out for its open, informal approach to real-world vein care. Live cases, candid discussions, and true cross-disciplinary exchange—less conference, more conversation.
The conference provided an important opportunity to engage with physicians, exchange clinical insights, and take part in discussions shaping the future of venous care, alongside vascular surgeons, interventional radiologists, and phlebologists from around the world.
This milestone marks a major regulatory achievement and formally establishes the pathway for the company’s entry into the U.S. market. The clearance enables VVT Medical to begin commercial activities in the United States, supporting broader adoption of its technology by physicians and advancing the company’s global growth strategy.
